Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Clonal Dissemination of Highly Virulent Extended-Spectrum Beta Lactamase-Producing Escherichia coli Strains Isolated From the Urine of Non-Hospitalised Patients in Zagreb Region (CROSBI ID 134970)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Vraneš, Jasmina ; Marijan, Tatjana ; Bedenić, Branka ; Mlinarić-Džepina, Ana ; Katić, Stjepan ; Kalenić, Smilja Clonal Dissemination of Highly Virulent Extended-Spectrum Beta Lactamase-Producing Escherichia coli Strains Isolated From the Urine of Non-Hospitalised Patients in Zagreb Region // International journal of antimicrobial agents, 31 (2008), Supplement 1; 19-24

Podaci o odgovornosti

Vraneš, Jasmina ; Marijan, Tatjana ; Bedenić, Branka ; Mlinarić-Džepina, Ana ; Katić, Stjepan ; Kalenić, Smilja

engleski

Clonal Dissemination of Highly Virulent Extended-Spectrum Beta Lactamase-Producing Escherichia coli Strains Isolated From the Urine of Non-Hospitalised Patients in Zagreb Region

Recent data suggest that extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli is an emergent cause of urinary tract infections in non-hospitalised patients in different countries. The aim of this study was to characterise ESBL-producing E.coli strains isolated from the urine of outpatients in the Zagreb region of Croatia. During the 5-month study period, a total of 2451 E. coli strains were isolated from the urine of non-hospitalised patients with significant bacteriuria. A total of 39 ESBL-producing E.coli strains (1.59%) were collected and characterised.

community-acquired urinary tract infections; extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli; clonal dissemination

Urinary Tract Infections Supplement, International Symposia on Urinary Tract Infection Weimar and Munich, Germany Edited by K.G. Naber, T. Matsumoto, L. Nicolle and R. Funfstuck Astellas Pharmaceutical Co. Ltd, Daiichi Pharmaceutical Co. Ltd, Dainippon Sumitomo Pharmaceutical Co. Ltd, Meiji Seika Kaisha and Takeda Chemical Industries Ltd, Toyamakagaku Pharmaceuticals and Zambon Group Spa. This supplement of the International Journal of Antimicrobial Agents deals with an update of current concepts of the diagnosis and treatment of urinary tract infections (UTI) and prostatitis based on two symposia in June 2006 in Weimar, Germany, and during the 25th International Congress of Chemotherapy in cooperation with the 17th European Congress of Clinical Microbiology and Infectious Diseases 30 March– 3 April 2007 in Munich, Germany

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

31 (Supplement 1)

2008.

19-24

objavljeno

0924-8579

Povezanost rada

Temeljne medicinske znanosti, Kliničke medicinske znanosti, Javno zdravstvo i zdravstvena zaštita

Indeksiranost